DrugLab118 USA launches in the US with campus drink-spiking tests

DrugLab118 USA said it is entering the U.S. market with forensic drink- and drug-detection programs aimed first at universities, as campuses face pressure to better prevent and respond to drink spiking. The company plans to expand the model to employers, hospitality venues and other organizations after the university rollout.

Why it matters: - DrugLab118 USA is targeting a growing campus safety problem: drink spiking and substance misuse. - The company is pitching detection as part of a broader prevention framework for universities that face Title IX and Clery Act responsibilities. - The initial focus on higher education could shape how campuses handle testing, awareness and response protocols.

What happened: - DrugLab118 USA announced its entry into the United States market on Sept. 30, 2026. - The company said it is distributing its forensic-based detection technology nationwide. - The first rollout will center on a university program designed to support campus safety frameworks. - DrugLab118 USA said it is contacting universities across the country to discuss partnerships.

The details: - DrugLab118 USA plans to work with institutions to design, launch and maintain prevention programs, not just supply test kits. - The proposed campus model includes DrinkDetective tests for orientation kits, residence halls and campus venues. - The model also includes visible awareness materials and guidance for using testing in welfare, safe-ride and bystander-intervention programs. - DrugLab118 was founded in the United Kingdom in 2003. - The company said it was the first business to commercialize rapid tests based on laboratory-validated forensic methodologies. - Chief Scientific Officer Jim Campbell, a former Home Office forensic scientist, leads the scientific work. - DrinkDetective and DrugDetective hold United States patent protection. - Company validation data show 97% to 100% agreement with gas chromatography-mass-spectrometry laboratory reference methods. - DrugLab118 technology is already used by police forces, local councils and venue operators in the United Kingdom and is licensed through partners in Spain. - The U.S. portfolio includes DrinkDetective, DrugDetective and FentanylDetective. - FentanylDetective is a rapid cassette test that detects fentanyl and nine of its analogues. - The company said more than 250,000 Americans have died from fentanyl since 2021, often after unknowingly ingesting it mixed into other substances. - DrugLab118 USA was incorporated in 2024 and is a division of Altrova Health Inc. - Altrova Health Inc. trades on the CSE as ROVA, on OTCQB as ATVHF and on the FSE as WF8.

Between the lines: - DrugLab118 USA is positioning testing as a visible deterrent, not just a response tool. - The company’s message to campuses is that making testing familiar and accessible could reduce opportunities for drink spiking. - The emphasis on universities suggests the company sees higher education as the fastest path to adoption and credibility in the U.S. market. - The broader pitch also ties campus safety to reputational and legal risk for institutions.

What's next: - DrugLab118 USA said it will keep building university partnerships around a sustainable campus safety framework. - After the university program, the company plans to expand support to employers, hospitality and nightlife venues, and other public and private organizations. - University leaders, campus safety teams and Title IX coordinators can contact DrugLab118 USA about partnerships. - More information is available here.

The bottom line: - DrugLab118 USA is using its U.S. launch to sell a campus safety model built around rapid detection, deterrence and ongoing prevention.